Recent progress in neonatal hyperoxic lung injury

Tian Rao1, Yiyang Zhou1, Chizhang Chen2

  • 1Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.

PubMed

Insights

Premature infant survival is up, but neonatal hyperoxia lung injury and bronchopulmonary dysplasia (BPD) are increasing. This review examines sex differences in BPD development and treatment, offering insights for future research.

Area of Science:

  • Neonatology
  • Pediatric Pulmonology
  • Biomedical Research

Background:

  • Neonatal intensive care advances have improved survival rates for premature infants.
  • This progress correlates with a rise in neonatal hyperoxia lung injury and bronchopulmonary dysplasia (BPD).
  • The precise pathogenesis of BPD remains incompletely understood, with multiple contributing factors suspected.

Purpose of the Study:

  • To analyze and summarize existing research on sex differences in neonatal hyperoxia lung injury and BPD.
  • To explore the potential pathogenic mechanisms underlying these conditions, considering sex as a factor.
  • To review treatment progress and therapeutic strategies for hyperoxic lung injury in neonates.

Main Methods:

  • Literature review and synthesis of recent studies.
  • Analysis of preclinical and clinical data on neonatal hyperoxia lung injury.
  • Examination of research investigating sex-specific effects on BPD development and outcomes.

Main Results:

  • Emerging evidence suggests sex plays a significant role in the susceptibility and progression of neonatal hyperoxia lung injury.
  • Various prenatal and postnatal factors, alongside potential sex-based biological differences, contribute to BPD pathogenesis.
  • Several therapeutic agents have shown promise in preclinical models for mitigating hyperoxic lung injury.

Conclusions:

  • Understanding sex differences is crucial for a comprehensive approach to neonatal hyperoxia lung injury and BPD.
  • Further research into sex-specific mechanisms can guide the development of targeted therapies.
  • This review provides a foundation for future clinical and basic science investigations in the field.

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
217
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
135
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
153
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
183